Summary
64 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 67% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- It bought back its own shares for $3.37M in the last fiscal year, 6.8% of its market value.
- It earns 13 USD a year on every 100 USD of invested capital.
What to watch
- Repaying its net debt would take 5.0 years of operating profit.
- Out of every 100 USD of revenue, only 3.2 USD is left as net profit.
- Revenue growth is slowing: 5.2% a year over the last 3 years against 11% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 8.5 USD for 1 USD of yearly profit. Over the last five years it was 27.8 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 5.2% a year. Earnings per share grew by 67% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 40 USD
- Sales and administration 52 USD
- Taxes and other 4.8 USD
- Net profit 3.2 USD
Net profit, industry median (Medical - Care Facilities) 6.7 USD
Out of every 100 USD of revenue, 3.2 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $4 is 254% above today's price. 86% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product Revenue 78%
- Dietary Supplements 18%
- Service Revenue 2.2%
- Other Service Revenue 1.2%
- Training Service Revenue 0.5%
By region
- UNITED STATES 99%
- Non-US 0.5%
Product Revenue brings in 78% of revenue. Other Service Revenue grew fastest, by 102% a year.
Segments in detail